THRB and metabolic dysfunction-associated steatohepatitis: In summary, Kylo-0603-a highly tissue- and target-selective, low-toxicity THR-β agonist—exhibits substantial therapeutic potential for managing MASH and represents a promising novel treatment option for affected patients.